nipah
viru
niv
hendra
viru
hev
recent
emerg
zoonot
paramyxovirus
exclus
group
within
new
genu
henipaviru
virus
caus
fatal
diseas
wide
rang
speci
includ
human
niv
hev
continu
reemerg
sporad
bangladesh
australia
respect
current
therapeut
vaccin
avail
treat
henipaviru
infect
classifi
pathogen
rna
interfer
rnai
process
doublestrand
rna
direct
sequencespecif
degrad
messeng
rna
anim
plant
cell
small
interf
rna
sirna
mediat
rnai
inhibit
gene
express
homolog
mrna
preliminari
studi
suggest
rnai
may
use
approach
develop
novel
therapi
highli
lethal
pathogen
eight
niv
sirna
molecul
four
l
four
n
gene
specif
two
hev
n
gene
specif
two
nonspecif
control
sirna
molecul
design
test
abil
inhibit
henipaviru
minigenom
replic
system
requir
use
live
viru
addit
live
viru
infect
vitro
minigenom
assay
three
four
sirna
target
l
gene
niv
effect
inhibit
replic
contrast
niv
n
gene
sirna
effect
reduc
live
niv
replic
suggest
inhibit
earli
abundantli
express
gene
transcript
may
effect
later
less
abund
transcript
addit
sirna
effect
niv
infect
partial
effect
inhibitor
hev
infect
invers
correl
number
nucleotid
mismatch
efficaci
sirna
inhibit
observ
demonstr
rnai
effect
inhibit
henipaviru
replic
vitro
novel
approach
may
provid
effect
therapi
highli
lethal
zoonot
pathogen
past
decad
number
novel
viral
diseas
emerg
particularli
area
australia
southeast
asia
mackenzi
field
viral
diseas
includ
highli
pathogen
zoonot
hendra
viru
hev
nipah
viru
niv
negativesens
singlestrand
rna
virus
belong
new
genu
henipaviru
paramyxovirida
famili
niv
emerg
peninsula
malaysia
chua
et
al
close
relat
hev
sequenc
homolog
niv
emerg
eastern
australia
murray
et
al
hev
niv
neurolog
pneumon
tropism
mackenzi
field
two
human
hev
fatal
succumb
either
acut
respiratori
diseas
enceph
murray
et
al
b
osullivan
et
al
hors
hev
infect
present
commonli
acut
respiratori
syndrom
mackenzi
field
niv
infect
predomin
clinic
syndrom
human
encephalit
smaller
number
respiratori
distress
pig
niv
infect
characteris
acut
fever
respiratori
involv
without
neurolog
sign
mackenzi
field
virus
continu
reemerg
almost
annual
basi
niv
respons
mani
infect
year
bangladesh
neighbour
india
case
fatal
rate
icddr
icddr
icddr
b
initi
niv
outbreak
malaysia
result
human
case
enceph
includ
death
attempt
control
outbreak
million
pig
cull
major
human
case
male
direct
contact
pig
pig
product
epidemiolog
evid
suggest
primari
mean
spread
farm
region
movement
pig
mackenzi
field
seroepidemiolog
studi
confirm
reservoir
host
virus
fruit
bat
genu
pteropu
subord
megachiroptera
yob
et
al
young
et
al
propos
niv
pass
bat
pig
initi
outbreak
daszak
et
al
mackenzi
et
al
howev
mani
recent
outbreak
niv
bangladesh
india
appar
associ
anim
sourc
probabl
epidemiolog
investig
may
inadequ
demonstr
mackenzi
field
particular
concern
recent
observ
humantohuman
transmiss
bangladesh
outbreak
seen
either
niv
hev
gurley
et
al
significantli
niv
isol
human
respiratori
secret
gurley
et
al
current
vaccin
postexposur
therapeut
specif
indic
henipaviru
infect
limit
nonrandomis
trial
ribavirin
initi
niv
outbreak
malaysia
show
ribavirin
therapi
reduc
mortal
associ
acut
niv
enceph
chong
et
al
studi
report
seriou
side
effect
ribavirin
associ
rang
side
effect
primarili
relat
haemolyt
anaemia
de
franceschi
et
al
ribavirin
also
shown
effect
hev
vitro
viru
yield
reduc
wright
et
al
recent
studi
show
analogu
ribavirin
ribavirin
abl
prevent
mortal
five
six
anim
hamster
model
niv
infect
georgescourbot
et
al
suggest
replic
inhibitor
may
effect
henipavirus
number
therapi
option
explor
experiment
includ
activ
passiv
vaccin
fusion
inhibit
receptor
blockad
clearli
need
advanc
area
rna
interfer
rnai
conserv
eukaryot
pathway
involv
rnaguid
gene
silenc
rnai
consist
sever
pathway
sequencespecif
mrna
degrad
core
featur
rnai
detect
organ
product
small
interf
rna
sirna
hammond
long
dsrna
cleav
enzym
call
dicer
sirna
sirna
incorpor
complex
call
rnainduc
silenc
complex
risc
mediat
gene
silenc
number
studi
demonstr
inhibit
replic
rna
virus
vitro
rnai
includ
polio
viru
gitlin
et
al
hiv
fan
et
al
han
et
al
novina
et
al
hepat
c
viru
yokota
et
al
sever
acut
respiratori
syndrom
sar
viru
zheng
et
al
also
report
vivo
inhibit
virus
rnai
includ
hepat
b
viru
giladi
et
al
mccaffrey
et
al
foot
mouth
diseas
viru
chen
et
al
data
first
rnai
therapeut
enter
human
clinic
develop
infecti
diseas
promis
rnai
therapeut
treatment
respiratori
syncyti
viru
rsv
infect
demonstr
drug
safe
well
toler
administ
intranas
adult
human
volunt
phase
clinic
trial
devincenzo
et
al
studi
indic
rnai
enorm
therapeut
potenti
number
seriou
infecti
diseas
henipavirus
appear
good
target
inhibit
via
rnai
rna
virus
without
dna
intermedi
entir
life
cycl
genom
rna
henipavirus
neg
sens
transcript
must
occur
viral
protein
express
transcript
complex
consist
polymeras
l
phosphoprotein
p
protein
initi
transcript
terminu
genom
rna
monocistron
cap
polyadenyl
mrna
synthes
viral
gene
intergen
region
consist
gaa
trinucleotid
exist
gene
immedi
upstream
gene
junction
transcript
complex
encount
stop
signal
either
proce
initi
transcript
next
gene
downstream
disengag
viral
rna
reiniti
transcript
terminu
therefor
rel
abund
viral
transcript
vari
invers
distanc
terminu
genom
free
nucleoprotein
n
accumul
cytoplasm
polymeras
switch
transcript
genom
replic
read
stop
signal
intergen
region
synthes
fulllength
plu
sens
viral
rna
serv
templat
synthesi
neg
sens
genom
rna
bellini
et
al
lamb
et
al
unlik
vaccin
requir
recipi
normal
immun
system
sirnabas
treatment
depend
function
immun
system
henc
may
use
elderli
immunocompromis
individu
well
studi
prepar
sirna
use
commerci
avail
kit
target
nucleocapsid
n
larg
polymeras
l
gene
niv
hev
specif
inhibit
viru
replic
indic
sirna
function
measur
reduct
replic
henipaviru
minigenom
halpin
et
al
magoffin
et
al
reduct
viral
rna
protein
express
infect
cell
cultur
cell
grown
eagl
minim
essenti
medium
contain
earl
salt
emem
antibiot
uml
penicillin
gml
streptomycin
gml
fungizon
foetal
calf
serum
tryptos
phosphat
broth
addit
cell
cultur
presenc
mgml
geneticin
hev
isol
vero
cell
lung
hors
infect
brisban
outbreak
octob
murray
et
al
passag
five
time
vero
cell
follow
tripl
plaqu
purif
five
passag
vero
cell
previous
describ
hyatt
selleck
niv
isol
vero
cell
brain
human
fatal
infect
malaysian
outbreak
passag
three
time
vero
cell
doubl
plaqu
purifi
passag
three
time
vero
cell
previous
describ
shiell
et
al
hev
niv
stock
titer
adjust
tcid
ml
initi
small
interf
rna
templat
oligonucleotid
sequenc
target
code
sequenc
nipah
viru
n
l
genbank
access
design
use
dharmacon
sidesign
centr
algorithm
http
wwwdharmaconcom
designcenterdesigncenterpageaspx
design
includ
leader
sequenc
nucleotid
nn
total
gc
content
base
sequenc
transcript
ambion
sirna
templat
design
tool
http
wwwambioncom
techlibmiscsilenc
sirna
templatehtml
silenc
tm
sirna
construct
kit
highestrank
result
select
construct
sirna
total
four
select
individu
gene
sirna
construct
silenc
tm
sirna
construct
kit
ambion
accord
manufactur
instruct
subsequ
experi
led
us
design
addit
two
hevspecif
sirna
molecul
describ
sirna
also
design
enhanc
fluoresc
green
protein
egfp
gene
provid
knockdown
control
initi
minigenom
studi
nonspecif
target
sirna
influenza
acid
polymeras
pa
gene
also
construct
oligonucleotid
templat
use
synthes
sirna
use
studi
genework
list
tabl
collabor
partner
initi
construct
minigenom
encod
niv
rna
analogu
code
region
viral
gene
replac
negativesens
copi
chloramphenol
transferas
cat
report
gene
halpin
et
al
system
subsequ
enhanc
modifi
report
system
involv
replac
cat
report
egfp
report
gene
magoffin
et
al
utilis
hev
minigenom
renilla
luciferas
luc
report
gene
gift
linfa
wang
briefli
construct
construct
egfp
report
minigenom
dna
fragment
contain
niv
l
utr
niv
trailer
region
promot
sequenc
amplifi
pcr
second
dna
fragment
contain
niv
leader
region
niv
n
utr
hepat
delta
viru
ribozym
hdv
sequenc
two
termin
sequenc
also
amplifi
pcr
cat
report
gene
remov
plasmid
digest
dna
part
ligat
gener
pnivgfp
phevluc
minigenom
precis
initi
site
promot
selfcleavag
rna
end
hdv
ribozym
ensur
minigenom
ident
genom
termini
complet
viral
genom
rna
halpin
et
al
magoffin
et
al
rule
six
maintain
minigenom
paramyxovirus
n
p
l
gene
requir
genom
replic
neumann
et
al
report
gene
detect
plasmid
encod
minigenom
niv
n
gene
niv
p
gene
niv
l
gene
transfect
mammalian
cell
halpin
et
al
magoffin
et
al
niv
support
plasmid
consist
niv
n
p
l
gene
clone
individu
express
vector
respect
wee
use
interchang
hev
minigenom
halpin
et
al
minigenom
transcrib
polymeras
rna
molecul
contain
exact
copi
noncod
region
genom
rna
niv
gener
minigenom
system
support
plasmid
transfect
babi
hamster
kidney
bhk
cell
provid
polymeras
activ
recombin
cell
line
stabli
express
rna
polymeras
ito
et
al
use
minigenom
experi
gift
biao
cell
monolay
seed
plate
cellswel
l
emem
incub
overnight
c
optimum
ratio
plasmid
concentr
minigenom
assay
predetermin
mixtur
g
minigenom
plasmid
g
n
plasmid
g
p
plasmid
g
l
plasmid
minigenom
assay
lipofectamin
invitrogen
ad
plasmid
dna
ratio
l
g
dna
serum
free
emem
ad
bring
final
sampl
volum
l
incub
min
room
temperatur
l
serum
free
emem
ad
sampl
transfect
mix
ad
cell
allow
incub
c
co
h
time
transfect
mix
remov
replac
growth
media
minigenom
assay
perform
replic
per
plate
experi
carri
least
three
time
luc
report
minigenom
experi
incub
h
l
chemiluminesc
substrat
steadyglo
promega
ad
incub
min
plate
read
luminoskan
ascent
luminomet
thermo
fisher
scientif
waltham
usa
use
ms
integr
per
well
sirna
construct
describ
dilut
work
stock
solut
transfect
mix
contain
sirna
lipofectamin
prepar
l
g
sirna
mix
g
lipofectamin
ratio
follow
addit
serum
free
emem
bring
final
sampl
volum
l
incub
min
room
temperatur
l
serum
free
emem
ad
sampl
bring
concentr
sirnawel
nm
simplifi
sirna
screen
experi
singl
dose
nm
chosen
review
vitro
sirna
transfect
literatur
indic
typic
effect
dose
viral
inhibit
transfect
mix
ad
cell
allow
incub
c
co
h
time
transfect
mix
remov
replac
growth
media
describ
cell
transfect
test
irrelev
sirna
follow
infect
niv
hev
monolay
seed
plate
l
per
well
incub
overnight
c
h
cell
transfect
nm
sirna
incub
h
plate
taken
laboratori
medium
remov
l
viru
solut
ad
follow
incub
min
c
h
virus
stock
solut
dilut
final
concentr
tcid
l
niv
tcid
l
hev
min
inoculum
remov
l
growth
media
ad
well
follow
overnight
incub
c
unprotect
cell
develop
syncytia
overnight
cultur
detect
immunofluoresc
viral
protein
follow
day
media
remov
cell
fix
icecold
methanol
min
remov
laboratori
air
dri
h
prior
immunofluoresc
label
fix
dri
plate
wash
phosphatebuff
salin
mm
pb
ph
contain
vv
tween
pbst
block
solut
bsa
pbst
ad
fix
cell
incub
c
min
block
cell
wash
three
time
pbst
follow
incub
lwell
antinivhev
n
protein
antibodi
min
c
incub
cell
wash
three
time
pbst
follow
incub
goat
antirabbit
alexafluor
conjug
invitrogen
c
min
dark
nuclear
stain
gml
dapi
icn
biomed
costa
mesa
usa
ad
secondari
antibodi
solut
incub
immunolabel
stain
cell
wash
three
time
pbst
cover
l
pb
prevent
cell
fluorophor
dri
syncytia
number
quantifi
use
imag
analysi
microscopi
previous
describ
porotto
et
al
briefli
cell
visual
use
invert
fluoresc
microscop
olympu
imag
captur
use
camera
olympu
imag
analysi
perform
use
analysi
imag
analysi
softwar
soft
imag
system
gmbh
munster
germani
overnight
viru
infect
viral
media
remov
cell
l
cell
lysi
buffer
rlt
qiagen
contain
ad
directli
well
plate
cell
lysat
aspir
pcr
tube
remov
laboratori
rna
extract
use
qiagen
rneasi
mini
kit
per
manufactur
instruct
rna
elut
final
volum
l
rnase
free
water
sampl
store
c
prior
taqman
pcr
analys
primer
taqman
probe
detect
niv
hev
genom
sequenc
design
n
gene
sequenc
niv
hev
respect
use
criteria
specifi
primer
express
softwar
version
appli
biosystem
foster
citi
ca
specif
niv
taqman
primer
probe
reaction
condit
use
previous
report
mungal
et
al
hevspecif
oligonucleotid
primer
fluorogen
nucleas
taqman
probe
rrna
use
normal
variat
rna
extract
oligonucleotid
primer
rrnaf
rrnar
fluorogen
nucleas
taqman
probe
rrna
rrnavic
taqman
pcr
oligonucleotid
primer
probe
sequenc
use
studi
avail
request
assay
perform
triplic
use
onestep
protocol
consist
initi
revers
transcript
reaction
follow
immedi
cdna
amplif
taqman
reagent
purchas
appli
biosystem
except
primer
obtain
genework
rna
ml
ad
l
pcr
mix
well
microamp
optic
reaction
plate
contain
l
taqman
onestep
pcr
mastermix
l
multiscribernas
inhibitor
l
distil
water
l
niv
hev
forward
revers
primer
l
hev
niv
famlabel
probe
l
rrnaf
rrnar
l
rrnaviclabel
probe
sampl
amplifi
geneamp
sequenc
detect
system
appli
biosystem
use
follow
program
c
min
cycl
c
min
cycl
c
c
cycl
linear
regress
analysi
use
quantifi
niv
hev
rna
base
cdna
standard
correct
sampl
variat
ct
valu
viral
genom
sampl
normal
rrna
express
viral
genom
express
rel
standard
cdna
dilut
pg
cdna
gene
specif
silenc
evalu
minigenom
assay
vitro
live
viru
infect
sirna
design
target
like
suppress
henipaviru
replic
system
eg
n
l
gene
total
sirna
design
produc
tabl
eight
sequencespecif
sirna
target
niv
four
target
l
gene
niv
four
n
gene
niv
two
sequencespecif
sirna
target
hev
n
gene
one
irrelevantnonspecif
sirna
neg
control
one
sirna
target
gfp
posit
control
previou
studi
indic
sirna
overhang
uu
dinucleotid
effect
consequ
rna
transcript
use
chemic
synthesi
begin
aa
dinucleotid
elbashir
et
al
addit
chemic
synthesi
make
use
rna
polymeras
nt
sequenc
complementari
promot
sequenc
also
ad
design
oligonucleotid
kim
colleagu
previous
suggest
bp
sirna
effect
mer
kim
et
al
order
evalu
hypothesi
n
gene
specif
sirna
utilis
current
studi
nucleotid
length
l
gene
specif
sirna
mer
follow
synthesi
concentr
end
product
determin
use
nanodrop
spectrophotomet
thermo
scientif
wilmington
de
usa
product
analyz
gel
electrophoresi
concentr
sirna
rang
ngl
sampl
show
band
expect
size
agaros
gel
data
shown
initi
experi
evalu
optimum
plasmid
ratio
sirna
efficaci
perform
use
cell
transfect
niv
minigenom
encod
egfp
report
data
shown
howev
quantit
gfp
express
monolay
requir
intens
digit
microscopi
imag
analysi
prompt
us
modifi
system
one
amen
autom
screen
subsequ
experi
perform
use
hev
minigenom
construct
contain
firefli
luciferas
luc
report
halpin
colleagu
halpin
et
al
show
support
plasmid
hev
niv
minigenom
interchang
enabl
simpl
substitut
without
extens
reoptimis
luciferasebas
assay
sensit
gfpbase
assay
time
measur
express
report
gene
reduc
h
vastli
improv
cell
viabil
due
lipofectamin
toxic
preliminari
studi
evalu
optimum
transfect
effici
minim
lipofectamineinduc
toxic
indic
transfect
carri
h
follow
remov
transfect
media
replac
mainten
media
utilis
luc
minigenom
assay
sirna
target
n
gene
niv
partial
inhibit
hev
minigenom
replic
inhibit
two
four
l
gene
specif
sirna
effect
inhibit
replic
fig
minigenom
lack
one
support
plasmid
includ
neg
control
demonstr
minim
replic
evidenc
reduc
luciferas
activ
fig
transfect
sirna
nm
prior
viru
infect
cell
show
three
four
sirna
target
n
gene
niv
effect
inhibit
viral
replic
niv
indic
reduct
number
syncytia
fig
fig
sirna
inhibit
luciferas
express
use
hev
minigenom
cell
transfect
hev
minigenom
encod
luciferas
report
gene
support
plasmid
minig
n
p
l
togeth
differ
sirna
nm
test
valu
express
control
well
minig
n
p
l
mean
se
six
biolog
replic
well
miss
l
gene
plasmid
minig
serv
neg
control
minig
minigenom
n
nucleocapsid
p
phosphoprotein
l
polymeras
contrast
none
sirna
target
l
gene
niv
show
effect
inhibit
viral
replic
fig
interestingli
three
n
target
sirna
one
equal
effect
hev
inhibit
two
significantli
less
effect
hev
inhibit
order
investig
effect
sequenc
sirna
align
multipl
align
clustal
w
niv
hev
determin
homolog
tabl
align
show
sirna
prove
effect
inhibit
hev
niv
contain
nt
mismatch
compar
hev
nucleotid
sequenc
furthermor
contain
nt
mismatch
result
inhibit
hev
infect
respect
evalu
whether
decreas
sirna
efficaci
silenc
target
sequenc
inhibit
viral
replic
relat
nt
mismatch
hevspecif
sirna
design
hev
sequenc
ident
nucleotid
posit
niv
design
hev
hev
cell
transfect
sirna
infect
viru
describ
fig
sirna
inhibit
live
niv
hev
cell
transfect
differ
sirna
nm
test
h
posttransfect
l
viru
ad
cell
incub
h
fix
icecold
methanol
remov
laboratori
viral
protein
detect
use
immunofluoresc
imag
analysi
digit
imag
well
perform
determin
number
viral
syncytium
valu
express
inhibit
syncyti
number
viru
control
well
untreat
mean
se
biolog
replic
multipl
align
hev
niv
nucleotid
mismatch
sirna
sequenc
align
hev
sequenc
indic
result
show
hevspecif
sirna
effect
inhibit
hev
niv
fig
although
observ
less
overal
inhibit
previou
experi
despit
improv
homolog
hev
still
effect
hev
infect
contrast
equival
niv
sirna
inhibit
niv
result
support
hypothesi
mismatch
sirna
contain
less
effect
becom
silenc
target
one
mismatch
appear
minor
effect
term
efficaci
silenc
target
sequenc
two
mismatch
dramat
reduc
efficaci
sirna
silenc
target
evalu
possibl
synergist
effect
multipl
sirna
therapi
cocktail
two
sirna
nm
niv
test
determin
multipl
sirna
effect
inhibit
viral
replic
use
singl
sirna
cocktail
abl
inhibit
niv
replic
effect
hev
replic
despit
reduct
hev
replic
applic
alon
fig
given
concentr
sirna
cocktail
reduc
half
sirna
transfect
inhibit
niv
consider
suggest
cumul
effect
sirna
confirm
result
obtain
live
viru
assay
detect
base
viral
protein
express
viru
infect
also
quantifi
use
realtim
pcr
taqman
pcr
describ
previous
mungal
et
al
result
obtain
taqman
assay
correspond
well
result
obtain
live
viru
inhibit
assay
fig
three
niv
n
gene
specif
sirna
abl
inhibit
live
viru
niv
replic
also
reduc
viral
rna
level
hevspecif
sirna
inhibit
also
correspond
well
two
assay
fig
bhk
cell
infect
niv
transfect
nm
niv
niv
show
decreas
viral
rna
approxim
respect
bhk
cell
transfect
sirna
cocktail
nm
niv
nm
also
show
decreas
viral
genom
indic
usag
multipl
sirna
inhibit
viral
replic
may
provid
enhanc
therapeut
approach
given
addit
constraint
involv
perform
antivir
assay
agent
vitro
develop
surrog
assay
screen
evalu
antivir
import
niv
negret
et
al
negret
et
al
hev
porotto
et
al
porotto
et
al
pseudotyp
assay
recent
develop
provid
excel
surrog
assay
evalu
viru
entri
fusion
mechan
enabl
wider
access
potenti
antivir
evalu
howev
pseudotyp
virus
either
replic
defici
reli
replic
protein
pseudotyp
viru
vsv
may
applic
specif
henipaviru
gene
knockdown
subsequ
sirna
evalu
current
studi
compar
minigenom
replic
assay
halpin
et
al
also
requir
infecti
viru
live
viru
assay
evalu
candid
sirna
molecul
potenti
antivir
comparison
result
obtain
live
viru
assay
result
obtain
minigenom
assay
reveal
interest
observ
use
minigenom
two
four
sirna
target
l
gene
niv
effect
inhibitor
viral
replic
inhibit
express
luciferas
report
wherea
sirna
target
n
gene
niv
partial
inhibit
minigenom
replic
contrast
sirna
test
live
viru
infect
none
sirna
target
l
gene
effect
inhibitor
viral
replic
three
four
sirna
target
n
gene
effect
differ
within
two
assay
sirna
target
differ
gene
might
sever
explan
minigenom
replic
depend
express
support
protein
step
occur
natur
infect
cell
thu
dynam
sirna
inhibit
plasmid
gene
express
may
markedli
differ
situ
viru
gene
inhibit
minigenom
system
surrog
assay
use
evalu
sirna
inhibit
viral
replic
absenc
viral
protein
present
live
viru
use
suggest
result
obtain
use
surrog
assay
may
necessarili
correspond
result
obtain
vitro
use
live
virus
quit
simpli
minigenom
assay
rel
restrict
assay
system
contain
essenti
element
replic
might
explain
greater
efficaci
sirna
target
l
gene
encod
viral
polymeras
niv
compar
sirna
target
n
gene
altern
shorter
length
sirna
target
n
gene
nt
compar
l
gene
target
nt
may
reduc
strength
bind
target
sequenc
reduc
efficaci
experi
use
equival
length
sirna
molecul
need
address
fact
live
viru
assay
sirna
target
n
gene
effect
inhibit
viral
replic
l
gene
target
appear
littl
effect
appear
complex
may
reflect
rel
abund
n
protein
compar
l
protein
earli
stage
viral
replic
switch
polymeras
transcript
mode
replic
mode
thought
trigger
intracellular
accumul
viral
protein
probabl
n
protein
necessari
rna
encapsid
barik
bellini
et
al
lamb
et
al
current
studi
evalu
n
l
gene
target
sirna
inhibit
select
first
last
gene
express
henipavirus
order
evalu
effect
transcript
quantiti
sirna
efficaci
live
viru
n
gene
sirna
target
prove
much
effect
l
gene
target
suggest
transcript
quantiti
influenc
sirna
efficaci
identifi
sever
sirna
molecul
effect
inhibitor
niv
hev
infect
howev
number
addit
target
remain
test
viral
gene
transcript
abund
crucial
sirna
efficaci
molecul
target
phosphoprotein
p
gene
may
also
highli
effect
p
protein
play
essenti
role
format
function
polymeras
complex
p
gene
henipavirus
also
predict
encod
addit
three
protein
v
w
c
harcourt
et
al
wang
et
al
target
c
protein
known
shown
niv
p
v
w
protein
act
ifn
signal
jakstat
pathway
distinct
mechan
involv
direct
inhibit
domain
common
n
terminu
rodriguez
horvath
shaw
et
al
due
conserv
role
three
protein
region
particular
may
prove
attract
target
sirnamedi
inhibit
similarli
pivot
role
matrix
protein
viral
bud
indic
vlp
studi
ciancanelli
basler
suggest
gene
target
may
also
inhibit
key
point
viral
life
cycl
g
f
protein
might
appear
attract
target
due
central
role
receptor
bind
membran
fusion
respect
physic
exposur
antigen
pressur
make
suscept
mutat
facilit
viral
escap
antivir
therapi
escap
sirnamedi
inhibit
like
govern
quit
differ
antigen
mutat
pressur
anticip
surfac
protein
like
inher
variabl
unexpos
protein
harcourt
et
al
import
observ
current
studi
appar
cumul
effect
multipl
sirna
treatment
strategi
may
provid
effect
approach
current
avail
limit
develop
antivir
resist
singl
sirna
therapi
may
ultim
suscept
viral
escap
via
select
mutat
use
multipl
gene
target
make
viral
escap
much
less
like
addit
previou
studi
influenza
escap
mutant
suggest
like
reduc
viral
fit
herloch
et
al
ive
et
al
mckimmbreschkin
logic
combin
sever
barrier
viru
infect
multipl
sirna
target
reduc
likelihood
viral
escap
howev
studi
shown
effect
concentr
sirna
may
reach
plateau
kamath
et
al
suggest
rnaiinduc
silenc
complex
cell
satur
studi
multipl
sirna
target
necessari
adequ
evalu
effect
vitro
vivo
summari
use
surrog
minigenom
assay
live
viru
infect
assay
evalu
number
potenti
antivir
candid
sirna
molecul
deriv
n
l
gene
niv
identifi
number
n
gene
target
effect
live
viru
infect
addit
observ
invers
correl
number
nucleotid
mismatch
efficaci
sirna
inhibit
given
high
homolog
hev
niv
individu
viru
specif
may
attain
target
slightli
heterolog
region
altern
broadspectrum
antivir
activ
may
achiev
select
strictli
homolog
target
given
recurr
reemerg
virus
current
lack
therapeut
intervent
demonstr
rnai
effect
inhibit
henipaviru
replic
vitro
provid
novel
approach
may
provid
effect
therapi
highli
lethal
zoonot
pathogen
